By otakuyassine3@gmail.com 
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price hit a new 52-week low on Thursday . The stock traded as low as $40.61 and last traded at $41.06, with a volume of 2372453 shares. The stock had previously closed at $44.63.
Wall Street Analysts Forecast Growth
CRSP has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Wednesday, December 11th. Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, Barclays decreased their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $77.93.
View Our Latest Research Report on CRISPR Therapeutics
CRISPR Therapeutics Trading Down 8.0 %
The business has a 50-day moving average of $48.67 and a two-hundred day moving average of $50.96. The firm has a market cap of $3.50 billion, a P/E ratio of -14.51 and a beta of 1.62.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the business posted ($1.41) earnings per share. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.13 EPS for the current year.
Insider Activity
In other news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,382 shares of company stock valued at $2,744,179. Insiders own 4.10% of the company’s stock.
Institutional Trading of CRISPR Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Larson Financial Group LLC raised its stake in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after buying an additional 276 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics in the 2nd quarter worth about $35,000. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at about $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the third quarter worth approximately $43,000. Finally, Denver PWM LLC bought a new stake in CRISPR Therapeutics in the second quarter worth approximately $45,000. Institutional investors and hedge funds own 69.20% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.